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A B S T R A C T
Early stage testicular seminoma is a radiosensitive tumor. Its incidence has significantly increased during the last
decade especially in the young population. Although the therapy for testicular seminoma gives very satisfying results, the
evaluation of genome damage caused by the therapy is of a great importance in order to recognize possible related health
risks. The present study was performed on ten patients diagnosed with seminoma stage I; pT1/2N0M0S0, treated with
adjuvant radiotherapy (a radiation dose of 25 Gy divided in 16 fractions) after orchidectomy. To assess the possible exis-
tence of an increased baseline DNA/chromosome damage in patients we also selected the appropriate control group of ten
healthy men. The levels of primary DNA/chromosome damage in peripheral blood lymphocytes, as well as the dynamics
of their repair were studied using the alkaline comet assay, chromosome aberration and cytokinesis-block micronucleus
assay. Altogether four blood samples per patient were collected in the course of the therapy: before and after receiving the
first dose of radiotherapy, in the middle of the radiotherapy cycle, and after the last dose of radiotherapy. Other two fol-
low-up blood samples were collected six and twelve months after the cessation of therapy. As observed, the administration
of the first radiation dose significantly increased the levels of DNA damage in almost all patients compared to their base-
line values. Specific patterns of DNA damage were recorded in samples analyzed in the middle of radiotherapy and after
receiving the last dose, indicating the possibility of an adaptive response in some patients. The levels of chromosomal ab-
errations and the incidence of micronuclei also increased in the course of therapy but gradually declined during the fol-
low-up period. Our results confirmed the existence of post-irradiation damage in peripheral blood lymphocytes (and pos-
sibly in other non-target cells) of cancer patients which may represent a risk for the secondary cancer development.
Considering that the majority of patients with testicular cancer are of a younger age, they represent a population deserv-
ing special attention. As cytogenetic screening may detect high-risk individuals, it might be useful in regular medical
monitoring of seminoma patients after the successful therapy.
Key words: testicular seminoma, lymphocytes, DNA damage and repair, comet assay, chromosome aberrations, mi-
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Introduction
Testicular cancer is relatively rare and accounts for
1% of all male cancers. It is the most common malig-
nancy in men aged between 15–34, and its incidence has
more than doubled over the last 30–40 years1,2. About
40% of testicular cancer are pure seminoma. Testicular
cancer incidence in Croatia is on the rise. Age-standard-
ized incidence rates in Croatia have increased by 278%
(from 3.39 per 100,000 men in 1994 to 12.83 per 100,000
men in 2005)3.
Ionizing radiation is a proven mutagen4. It is impor-
tant to study the processes of DNA repair as well as qual-
itative and quantitative changes in cytogenetic biomar-
kers in seminoma patients. Short-term and long-term
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monitoring of cytogenetic biomarkers of testicular can-
cer patients after being treated with adjuvant irradiation
is important to recognize radiosensitive patients with a
high risk for secondary tumor development5,6. The re-
sults of previous cytogenetic studyes indicate the in-
crease of frequency of cytogenetic biomarkers, such as
the number of micronuclei, unstable chromosome aber-
rations in cancer patients treated with radiation therapy
in comparison with the healthy population7–11.
In this study, we investigated the level of primary and
residual chromosome damage in peripheral blood lym-
phocytes collected from the patients with testicular se-
minoma. As sensitive biomarkers the alkaline comet as-
say, analysis of structural chromosome aberrations and
cytokinesis-block micronucleus assay were used. We also
investigated inter-individual differences in the persis-
tence of the genome damage 6 months and one year after
the adjuvant radiotherapy. We also tried to evaluate
whether the results obtained by the cytogenetic end-
points might be useful as prognostic factors in the moni-




Investigation was performed in accordance with the
high standards of ethics. Before entering the study all
subjects were informed about the aim and the experi-
mental details and gave their signed consent for volun-
tarily participation. The work was approved by the na-
tional ethical committees on human experimentation
and complies with the principles laid down in the Decla-
ration of Helsinki.
Patients
The study population consisted of ten men diagnosed
with seminoma of testes (stage I; pT1/2N0M0S0), sub-
jected to surgical removal of tumors (orchidectomy) and
treated with adjuvant radiotherapy. Their median age
was 35 years (range: 23–49 years). Patients were inter-
viewed using a standardized questionnaire that covered
personal anamnesis data, along with occupational, medi-
cal, and other variables known to influence cytogenetic
endpoints. Three patients were smokers. All patients
were non-alcoholics, with no previous history of malig-
nant diseases or therapy by antineoplastic drugs or radi-
ation. Patients were not exposed to physical or chemical
agents in their living or working environment which
could influence the results of cytogenetic screening. Ana-
mneses and clinical data collected from patient records
are presented in Table 1.
The same diagnostic protocol was applied for all pa-
tients. Before the operation, they underwent a standard
diagnostic procedure (physical examination, blood tests
and tumor markers: AFP, bHCG, LDH, chest X-ray, CT of
the abdomen and pelvis). Adjuvant radiotherapy to para-
-aortic and ipsilateral iliac nodes was scheduled to start
within four weeks following the surgery, when patients
were in good clinical condition.
Patients were treated with external beam radiother-
apy (from the linear accelerator) using the radiation dose
of 25 Gy divided in 16 daily fractions. Two opposite
antero – posterior (AP-PA) fields of photons (energy:
15MV) were applied to para-aortal and ipsilateral iliacal
lymph nodes.
Radiation doses during the treatment were 1.56 Gy / 1
fr. after the 1st radiation (second blood sampling); 12.5
Gy / 8 fr. in the middle of radiotherapy (third blood sam-
pling); and 25 Gy / 16 fr. at the end of radiotherapy
(fourth blood sampling).
When radiotherapy was completed, patients under-
went standard diagnostic procedures and were regularly
monitored during the following year using conventional
clinical protocols.
Control group
Ten volunteer male blood donors of the similar age
(range: 22 to 50 years), and life-styles were selected as
the control group. All of them were healthy at the mo-
ment of blood sampling and interviews. They were not
occupationally exposed to genotoxic agents. None of
them reported alcohol consumption, medicine intake, the
presence of known inherited genetic disorders, family
history of testicular cancer or chronic diseases. Among
them there were 7 non-smokers and 3 smokers. For the
one-year period prior to the blood sampling, control sub-
jects had not been subjected to ionizing or non-ionizing
radiation for diagnostic or therapeutic purposes.
Methods
Blood sampling
Samples of venous blood (5 mL per each sampling
time) were collected in heparinized vacutainer tubes
(Becton Dickinson, N.J., USA). Patients were sampled six
times throughout the study. Using blood samples col-
lected before therapy, individual baseline values for each
method were estimated.
The pre-treatment blood sample (I) was collected on
day 1 of the first radiotherapy cycle, two hours prior to
the radiation. The response of peripheral blood leuko-
cytes to the radiotherapy was evaluated on blood samples
taken within two hours after the application of the first
dose (II), as well as in the middle of the radiotherapy cy-
cle (III) and within 2 hours after the last received radio-
therapy dose (IV). Two blood samples were taken 6
months (V), respectively 12 months (VI) after radiother-
apy.
The blood samples from the age-matched healthy men
were taken simultaneously during the study (a balanced
collection design was used).
All blood samples were taken in the morning. After
venepuncture, they were coded, cooled at +4 °C in the
dark and transferred to our laboratory. They were pro-
cessed immediately after transportation (within a maxi-
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mum of one-hour period after collection) by alkaline
comet assay, and cell cultures were launched for the anal-
ysis of structural chromosome aberrations (CA) and the
cytokinesis-block micronucleus assay (CBMN) following
the recommendations by International Atomic Energy
Agency (IAEA, 2001), ICPS guidelines (Albertini et al.,
2000) and the HUMN project12.
The comet assay was carried out under alkaline condi-
tions, as described by Singh et al.13. All chemicals, if not
specified, were purchased from Sigma Chemicals (St.
Louis, MO, USA). Two replicate slides per sample were
prepared. Agarose gels were prepared on fully frosted
slides coated with 1% and 0.6% normal melting point
(NMP) agarose. Blood samples (5 mL) were mixed with
0.5% low melting point (LMP) agarose, placed on the
slides and covered with a layer of 0.5% LMP agarose. The
slides were immersed for 1 h in freshly prepared ice-cold
lysis solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM
Tris-HCl, 1% Na-sarcosinate, pH 10) with 1% Triton
X-100 and 10% dimethyl sulfoxide (Kemika). Alkaline de-
naturation and electrophoresis were carried out at 4 °C
under dim lights in freshly prepared electrophoretic
buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13.0). After
20 min of denaturation, the slides were randomly placed
side by side in the horizontal gel-electrophoresis tank,
facing the anode. Electrophoresis at 25 V lasted another
20 min. After electrophoresis, the slides were gently
washed with a neutralisation buffer (0.4 M Tris-HCl, pH
7.5) three times at five-minute intervals. Slides were
stained with ethidium bromide (20 mg/mL) and stored at
4 °C in humidified sealed containers until analysis. Each
slide was examined using a 250x magnification fluores-
cence microscope (Zeiss) equipped with an excitation fil-
ter of 515–560 nm and a barrier filter of 590 nm. The to-
tal of 100 comets per sample were scored (50 from each of
two replicate slides). Comets were randomly captured at
a constant depth of the gel, avoiding the edges of the gel,
occasional dead cells and superimposed comets. Using a
black and white camera, the microscope image was trans-
ferred to a computer-based image analysis system (Co-
met Assay II, Perceptive Instruments Ltd.). To avoid the
variability, one well-trained scorer scored all comets. As a
measure of DNA damage, tail length and tail moment
were chosen. Moreover, cells were classified as either
»undamaged« or »damaged« by considering threshold
levels indicating the comets with a long-tailed nucleus
(LTN), i.e. the length over the 95th percentile of the dis-
tribution of the tail lengths among control samples14.
Chromosome aberration analysis was performed ac-
cording to International Atomic Energy Agency guide-
lines (IAEA, 2001). In brief, cultures were incubated in
vitro for 48 h in F-10 medium (Sigma) with 20% calf se-
rum (Sigma) and stimulated by phytohaemagglutinin
(PHA; Apogent). To arrest dividing lymphocytes in me-
taphase, colchicine (0.004%) was added 3 h prior to the
harvest. Preparations were made according to the stan-
dard procedure. Slides were stained with 5% Giemsa so-
lution (Sigma). All slides were coded and scored blindly
at 1000x magnification under oil immersion. Structural
chromosome aberrations were classified based on the
number of sister chromatids and breakage events in-
volved. Only metaphases containing 45–47 centromeres
were analysed. One hundred metaphases per sample (50
from each of two replicates) were analysed for the total
number and types of aberrations, as well as the percent-
age of aberrant cells.
Cytokinesis-block micronucleus assay (CBMN) was
performed using lymphocyte cultures according to the
standard protocol, with minor modifications (Fenech and
Morley, 1985). Lymphocyte cultures were incubated in
vitro in F-10 medium for 72 h. Cytochalasin B in final
concentration 6 mg/mL was added to the culture at 44 h.
Preparations were made according to the standard pro-
cedure. Slides were stained with 5% Giemsa solution
(Sigma). For MN identification the criteria of Fenech et
al.12 were used. MN scoring was performed on coded
slides at 1000x magnification under oil immersion. Alto-
gether 1000 binuclear (BN) cells per each sample were
scored. Total number of MN and their distribution were
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TABLE 1
ANAMNESTIC AND CLINICAL DATA OF CANCER PATIENTS INVOLVED IN THE STUDY.
Patient code BW (kg) / BH (cm) BMI Age Familial history of cancer Smoking habit
T1 75/183 22.1 33 – –
T2 80/175 25.0 41 – –
T3 80/187 22.9 23 – +
T4 89/184 24.4 49 + –
T5 76/170 25.3 40 + –
T6 103/185 30.1 26 – –
T7 116/175 37.2 37 – –
T8 90/180 27.1 37 – +
T9 65/183 19.4 26 + –
T10 70/177 22.2 31 + +
BW – body weight; BH – body height; BMI – body mass index
determined, along with the number of micronucleated
cells.
Statistical Analyses
Statistical analyses were carried out with the com-
mercial programme Statistica 7.0 (StatSoft, Tulsa, USA).
The extent of DNA damage, as recorded by the alkaline
comet assay, was analysed considering the parameters of
descriptive statistics: mean (±standard deviation), me-
dian and range of the comet parameters.
Variance homogeneity was tested by the Lindman’s
test prior to the analysis of correlation and between-
-group differences. Normality of distribution was tested
by using the Shapiro-Wilks’ W-test. Since the distribu-
tion of variables was not normal, nonparametric meth-
ods were used in further analyses. Differences between
groups of independent variables were analyzed using the
Mann-Whitney U-test and Kruskall-Wallis test. Fried-
man ANOVA test and Wilcoxon matched pairs test with
the downward adjustment of the a-level for multiple
comparisons between pairs were used to determine dif-
ferences between the groups of dependent variables. The
level of significance of correlation between the variables
and the correlation trend were analyzed using the Spear-
man Rank Order Correlation Test. Statistical signifi-
cance was defined as p<0.05 in all analyses.
Results
Alkaline Comet Assay
Distribution of comet tail lengths measured in blood
samples I–VI collected from seminoma patients through-
out the study is shown in Figure 1.
Individual values of comet tail lengths measured in
pre-treatment blood samples (I) ranged between 16.58±0.29
mm (T1) and 31.05±1.79 mm (T2). The group mean value
of tail lengths was 22.56±1.52 mm and the median 21.14
mm. Tail moments measured in the same samples ranged
between 3.40±0.08 (T4) and 5.61±0.13 (T8). The group
mean value of tail moments was 4.44±0.26 and the me-
dian 4.36.
The response of peripheral blood leukocytes to the ra-
diotherapy was evaluated on blood samples taken within
two hours after the application of the first dose (samples
II). The values of comet tail lengths measured in these
blood samples ranged between 14.92±0.40 mm (T1) and
62.07±2.97 mm (T5). The group mean value of tail len-
gths was 28.17±4.56 mm and the median 22.11 mm. Indi-
vidual tail moments were 3.22±0.11 (T1) to 9.85±0.56 (T5).
The group mean value of tail moments was 5.01±0.60
and the median 4.54.
In the middle of the radiotherapy cycle (sample III)
individual values of comet tail length ranged between
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TABLE 2
RESULTS OF THE COMET ASSAY AND CYTOGENETIC ENDPOINTS IN THE REFERENT POPULATION
Parameters X±SD Range of individual values
Comet tail length (mm) 13.79±1.07 12.45±0.72 – 15.26±1.24
LTN per 100 comets 1.90±2.77 0 – 7
Structural CA per 100 metaphases 0.55±0.37 0 – 1
Chromatid breaks 0.35±0.33 0 – 1
Chromosome breaks 0.10±0.31 0 – 1
Acentric fragments 0.10±0.21 0 – 1
Cells with structural CA 0.55±0.37 0 – 1
MN per 1000 binuclear cells 3.89±2.47 1 – 9
Micronucleated cells 3.44±1.88 1 – 7
with 1 MN 3.00±1.41 0 – 5
with 2 MN 0.44±0.73 0 – 2



























Fig. 1. The distribution of comet tail lengths in peripheral blood
leukocytes of testicular seminoma patients (N=10). Pre-treat-
ment blood sample (I) was collected on day 1 of the first radio-
therapy cycle, two hours prior to the irradiation. The response of
peripheral blood leukocytes to the radiotherapy was evaluated on
blood samples collected within two hours after the application of
the first dose (II), as well as in the middle of the radiotherapy cy-
cle (III) and within 2 hours after the last received radiotherapy
dose (IV). Two follow-up blood samples were taken 6 months (V),
respectively 12 months (VI) after the cessation of radiotherapy.
17.49±0.41 mm (T9) and 29.82±1.17 mm (T6). The group
mean value of tail lengths was 24.17±1.13 mm and the
median 24.64 mm. Corresponding tail moments were be-
tween 3.68±0.07 (T9) and 5.25±0.10 (T4), with the group
mean value of tail moments 4.46±0.16 and the median
4.52.
After the last received radiotherapy dose (samples IV)
the values of comet tail length ranged between 18.68±0.27
mm (T10) and 25.56±0.64 mm (T9), with the group mean
value 21.10±0.60 and the median 20.69. Tail moments
ranged between 3.75±0.07 (T3) and 6.14±0.11 (T6). The
group mean value of tail moments was 4.86±0.29 and the
median 4.39.
In blood samples taken 6 months (V) after radiother-
apy the values of comet tail lengths ranged between
17.55±0.41 mm (T5) and 21.74±1.19 mm (T8), with the
group mean value 19.51±0.51 and the median 19.59. Cor-
responding tail moments were 3.29±0.06 (T5) to 4.88±0.12
(T7). The group mean value of tail moments was 3.99±0.17
and the median 3.88.
The last blood sampling was done 12 months after ra-
diotherapy (sample VI). In these blood samples tail len-
gths ranged between 15.19±0.22 mm (T9) and 24.18±1.66
mm (T10). The group mean value of tail lengths was
17.18±0.18 mm and the median 16.53 mm. Corresponding
tail moments were between 3.31±0.06 (T4) and 4.36±0.22
(T10), with the group mean value 3.49±0.11 and the me-
dian 3.37.
The statistical evaluation of the data (Friedman
ANOVA test) confirmed the differences observed among
the patients and the sampling times as significant (tail
length: p<0.001; coefficient of concordance=0.411; aver-
age r=0.346; tail moment: p=0.008; coefficient of concor-
dance=0.311; average r=0.234).
The incidence of LTN comets was evaluated in paral-
lel with tail lengths and tail moments. The distribution
of LTN comets in six blood samples (I–VI) is shown in
Figure 2. The baseline frequency of LTN was 3–5/100
comets, with the mean value 4.40±0.22 and the median
4.50. Our results indicate the differential response of
patients to therapeutic irradiation. Some patients, for in-
stance T4 and T5, showed a marked increase of LTN fol-
lowing the administration of a single fraction of radia-
tion. Individual values recorded in blood samples II ran-
ged between 0–48 LTN/100 comets, with the mean value
13.90±5.79 and the median 5. In the majority of patients
the incidence of LTN increased in the middle or at the
end of the radiotherapy cycle. In blood samples III indi-
vidual values of LTN ranged between 0–46 LTN/100 com-
ets, with the mean value 17.40±4.95 and the median
14.50. In blood samples collected at the end of the radio-
therapy cycle there were 8.10±4.16 LTN/100 comets re-
corded (median: 2.00 range 0–37 LTN/100 comets). In
blood samples collected six months following the cessa-
tion of the therapy a relatively high number of LTN was
observed: 6.00±4.16 LTN/100 comets (median: 7.00, ran-
ge 0–13 LTN/100 comets). We assume that the increase of
LTN incidence in these blood samples was also related to
the diagnostic exposure, since before fifth blood sampling
the patients underwent diagnostic examinations. During
the next six months the number of LTN gradually de-
creased and in most patients it returned to pre-therapy
levels. The group mean value was 1.20±0.92 LTN/100
comets (median: 0, range 0–9 LTN/100 comets).
The statistical evaluation of the data (Friedman
ANOVA test) confirmed the differences regarding LTN
observed between the patients and the sampling times as
significant (p<0.002; coefficient of concordance=0.368;
average r=0.298).
The levels of primary DNA damage in healthy men
were more uniform than in seminoma patients and the-
refore would not be reported individually. Detailed data
obtained for the control group are shown in Table 2. The
statistical evaluation by the Mann-Whitney test indicates
that difference between the pre-therapy values of comet
tail lengths in seminoma patients and the matched heal-
thy controls was highly significant (p=0.0002). Similar
results were obtained for the LTN comets (p=0.0413).
Analysis of Structural CA
The total number of structural chromosome aberra-
tions recorded in pre-treatment blood samples (I) ranged
between 1% (T1, T2, T3, T9) and 4% (T6). The total
number of structural chromosome aberrations recorded
in blood samples taken after the application of the first
dose ranged between 3% (T9) and 12% (T8). In the mid-
dle of the radiotherapy cycle (sample III) the total num-
ber of structural chromosome aberrations ranged be-
tween 3% (T9) and 40% (T4). After the last received
radiotherapy dose (samples IV) the total number of struc-
tural chromosome aberrations ranged between 11% (T8)
and 86% (T4). In blood samples taken 6 months (V) after
radiotherapy the total number of structural chromosome
aberrations ranged between 8% (T8) and 48% (T2). In
blood samples taken one year after cessation of radio-
therapy (sample VI) the total number of structural chro-
mosome aberrations ranged between 5% (T3, T8) and
40% (T10). Among the patients studied, marked inter-in-
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Fig. 2. The distribution of LTN comets (LTN-long tailed nuclei)
in blood samples collected from testicular seminoma patients
(N=10) before (I), in the course (II,III) and after radiotherapy
(IV), as well as during the follow-up period (V, VI).
dividual differences were observed. The incidence of chro-
mosome aberrations (CA) in six blood samples (I–VI) is
given in Figure 3.
The total number of aberrant cells recorded in pre-
-treatment blood samples (I) ranged between 1% (T1, T2,
T3, T9) and 4% (T6). After the administration of the first
radiation dose (samples II) there were between 2% (T9)
and 9% aberrant cells recorded (T2). In the middle of the
radiotherapy cycle (sample III) the total number of aber-
rant cells ranged between 3% (T9) and 25% (T4). After
the last received radiotherapy dose (samples IV) the total
number of aberrant cells ranged between 6% (T6) and
48% (T4). During the follow-up period the number of ab-
errant cells decreased. In blood samples taken 6 months
(sample V) after radiotherapy the total number of aber-
rant cells ranged between 2% (T8) and 23% (T4). In
blood samples taken one year after the cessation of radio-
therapy the total number of aberrant cells ranged be-
tween 4% (T3, T8) and 17% (T10). Among the patients
studied, marked inter-individual differences were ob-
served.
In pre-treatment blood samples of almost all patients
aberrant cells contained only one structural chromosome
aberration. Cells with multiple aberrations were recor-
ded in later blood samplings (especially in the middle of
the radiotherapy cycle and after the last radiation dose
administered), when their distribution among the pa-
tients was similar. Distribution of aberrant cells with one
and those with more then one aberration in samples I–VI
is displayed in Figure 4. Figure 5 shows the correlation
between the cells with chromosome aberrations and mi-
cronucleated cells established in blood samples I–VI.
The statistical evaluation of the data (Friedman
ANOVA test) confirmed the differences regarding the to-
tal number of structural chromosome aberrations ob-
served between the patients and the sampling times as
significant (p<0.001; coefficient of concordance=0.647;
average r=0.608). The incidence of unstable aberrations
was also significant: acentric fragments (p<0.001; coeffi-
cient of concordance=0.699; average r=0.666) and dicen-
tric chromosomes (p<0.001; coefficient of concordance=
0.543; average r=0.342). The similar was observed for
the incidence of aberrant cells (p<0.001; coefficient of
concordance=0.592; average r=0.547), the incidence of
cells containing only one aberration (p=0.005; coefficient
of concordance=0.336; average r=0.262) and the inci-
dence of cells with multiple aberrations (p<0.001; coeffi-
cient of concordance=0.642; average r=0.602).
Detailed data obtained for the control group are re-
ported in Table 2. The statistical evaluation by the Mann-
-Whitney test indicates that pre-therapy values of struc-
tural CA and aberrant cells in seminoma patients were
significantly higher than in the matched healthy controls
(p=0.0009). However, in both groups we recorded similar
types of CA, mainly chromatid breaks. Chromosome break
was recorded in only one control subject and acentric
fragments in two of them.
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Fig. 3. The distribution of structural chromosome aberrations (CA)
in blood samples collected from testicular seminoma patients
(N=10) before (I), in the course (II,III) and after radiotherapy
(IV), as well as during the follow-up period (V, VI).
Box & Whisker Plot


















Fig. 4. The distribution of cells with one aberrations (white box)
and more than one aberration (grey box) in blood samples col-
lected from testicular seminoma patients (N=10) before (I), in the
course (II,III) and after radiotherapy (IV), as well as during the
follow-up period (V, VI).
Box & Whisker Plot



























Fig. 5. The correlation between the total number of cells with CA
and micronucleated cells in blood samples collected from testi-
cular seminoma patients (N=10) before (I), in the course (II,III)
and after radiotherapy (IV), as well as during the follow-up pe-
riod (V, VI).
Micronucleus assay
The incidence of micronucleated cells in pre-treat-
ment samples ranged between 8/1000 cells (T3) and
22/1000 cells (T2). After the administration of the first
radiation dose (samples II) there were between 12 (T3)
and 56 micronucleated cells /1000 cells recorded (T8). In
the middle of the radiotherapy cycle (sample III) the total
number of micronucleated cells ranged between 30/1000
cells (T10) and 110/1000 cells (T8). After the last re-
ceived radiotherapy dose (samples IV) the total number
of micronucleated cells ranged between 66/1000 cells
(T5) and 144/1000 cells (T8). Six months after radiother-
apy (samples V) the total number of micronucleated cells
ranged between 24/1000 cells (T9) and 80/1000 cells (T2).
One year after radiotherapy (sample VI) the total num-
ber of micronucleated cells ranged between 14/1000 cells
(T9) and 64/1000 cells (T2). The distribution of micro-
nucleated cells in blood samples I–VI is displayed in Fig-
ure 6.
Among the studied patients marked inter-individual
differences were observed. Micronucleated cells in pre-
-treatment blood samples of many patients contained
more than one MN. As observed, such cells appeared
more frequently in later blood samplings (especially in
the middle of the radiotherapy cycle and after last radia-
tion dose administered). In all patients and sampling
times micronucleated cells which contain one MN pre-
dominated over cells which contain more then one MN.
In two patients (T4 and T6) micronucleated cells with 4
micronuclei were also recorded.
Distribution of MN in blood samples I–VI is shown in
Figure 7. The total number of micronuclei in pre-treat-
ment sample ranged between 8 MN/1000 cells (T3) and
22 MN/1000 cells (T2 T4, T9). After the administration
of the first radiation dose (samples II) there were be-
tween 12 MN (T3) and 66 MN/1000 cells recorded (T8).
In the middle of the radiotherapy cycle (sample III) the
total number of micronuclei ranged between 34 MN/1000
cells (T10) and 128 MN/1000 cells (T8). After the last re-
ceived radiotherapy dose (samples IV) the total number
of micronuclei ranged between 86 MN/1000 cells (T7)
and 200 MN/1000 cells (T8). Six months after radiother-
apy (samples V) the total number of micronuclei ranged
between 28 MN/1000 cells (T9) and 100 MN/1000 cells
(T8). One year after radiotherapy (sample VI) the total
number of micronucleated cells ranged between 14 MN/
1000 cells (T9) and 70 MN/1000 cells (T4).
The statistical evaluation of the data (Friedman
ANOVA test) confirmed the differences regarding the to-
tal number of micronuclei observed between the patients
and the sampling times as significant (p<0.001; coeffi-
cient of concordance=0.954; average r=0.949). Similar
was observed for the incidence of micronucleated cells
(p<0.001; coefficient of concordance=0.922; average r=
0.913), micronucleated cells containing one MN (p< 0.001;
coefficient of concordance=0.877; average r=0.863) and
micronucleated cells containing two MN (p<0.001; coef-
ficient of concordance=0.888; average r=0.876).
Detailed data obtained for the control group are repor-
ted in Table 2. The statistical evaluation by the Mann-
-Whitney test indicates that pre-therapy values of MN in
seminoma patients were significantly higher than in the
matched healthy controls (p=0.0004). The similar result
was obtained for the micronucleated cells (p=0.0002). In
both groups micronucleated cells with 1MN predomi-
nated over those with 2 MN.
Discussion
Radiotherapy is one of the most evident examples of
intentionally induced DNA damage. Recent progress in
this field has improved the prognosis of cancer patients,
but in turn has brought about many complications. At-
tention is especially focused on the secondary cancer fol-
lowing radiotherapy, for which the risk is substantial15.
Since only a portion of the treated population would de-
velop a secondary cancer in the future, the biomonitoring
of patients after the successful therapy becomes essen-
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Fig. 6. The distribution of MN in blood samples collected from
testicular seminoma patients (N=10) before (I), in the course (II,III)
and after radiotherapy (IV), as well as during the follow-up pe-
riod (V, VI).
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Fig. 7. The distribution of micronucleated cells containing 1–4
MN in blood samples collected from testicular seminoma patients
(N=10) before (I), in the course (II,III) and after radiotherapy
(IV), as well as during the follow-up period (V, VI).
tial. The main idea is to detect sensitive subpopulations of
patients, often with inherited genome instability, which
is a precondition to the increased risk of secondary carci-
noma.
In the present study, the alkaline comet assay, chro-
mosome aberration and micronucleus assay were applied
for the evaluation of background and radiation-induced
DNA damage in patients diagnosed with seminoma who
were subjected to adjuvant radiotherapy. As known, early
stage seminoma is a radiosensitive tumor. Between 15%
and 20% of seminoma patients (stage I), relapse during
surveillance if they do not receive adjuvant radiation
therapy after orchidectomy. The median time to relapse
is approximately 12 months, but relapses may occur
more than 5 years following the therapy2,4.
The role of biomarkers as prognostic indicators for
genotoxic and carcinogenic risks is extensively investi-
gated. Among them, cytogenetic endpoints as chromo-
somal aberrations, sister chromatid exchange frequency,
and micronucleus frequency were mostly used16,17. Dur-
ing the last decade, the alkaline comet assay also gained
importance in clinical medicine as a sensitive tool that
enables the estimation of primary DNA damage directly
and in single cells18.
In this study the peripheral blood lymphocytes were
chosen as a model system as they are the favored cells for
most of the biomarker assays and established earlier as
suitable biodosimeters that integrate the effects of expo-
sure to exogenous and endogenous genotoxins19. Fur-
thermore, lymphocytes seemed to be suitable because of
their easy availability, synchronous population, low fre-
quency of spontaneous chromosomal aberrations, conve-
nient culture methods and simplicity of sample collec-
tion20. The last was particularly important in our study,
as we were able to collect the blood samples from the pa-
tients using minimal invasive procedure without putting
them in additional emotional or physical distress.
Our results showed that local fractionated radiother-
apy delivered to seminoma patients critically influenced
the levels of primary DNA damage, induced chromo-
somal aberrations and micronuclei in their peripheral
blood lymphocytes. These findings are in agreement with
the reports of other authors who investigated the im-
pacts of radio- or chemotherapy on non-target cells in
other cancer patients21–25.
Ionizing radiation causes a wide variety of DNA dam-
age, ranging from single- and double-strand breaks in
DNA, as well as DNA base modifications, oxidative dam-
age and alkali-labile lesions that may be easily converted
into strand breaks during alkaline denaturation and
therefore sensitively detected by the alkaline comet as-
say26–28. In addition to the direct ionization of DNA it
also causes an indirect ionization through reactive oxy-
gen species. The largest part of the radiation effect in ra-
diotherapy is mediated by free radicals. In such condi-
tions clusters of lesions or multiply damaged sites are
also formed and they significantly contributed to the
lethality of ionizing radiation. It is believed that the
more complex the lesion, the less likely repair or correct
repair would occur29.
Ionizing radiation deposits energy that injures or de-
stroys cells in the area being treated (the »target tissue«)
by damaging their genetic material, making it impossible
for these cells to continue to grow. Although radiation
damages both cancer cells and normal cells, the latter are
able to repair themselves and function properly. Small
frequent doses of radiation allow healthy cells time to re-
pair damage inflicted by the radiation. However, cancer
cells often are undifferentiated and have a lesser ability
to repair sub-lethal damage compared to most healthy
differentiated cells. As a result, cells with accumulated
DNA damage would die or proliferate more slowly. For
these reasons, radiation therapy is typically delivered
daily. The dose administered depends mainly on the tu-
mor type, but also on other factors: whether radiation is
given alone or with chemotherapy, before or after sur-
gery, the success of the surgery and its findings and many
other reasons. The typical dose for patients with semi-
noma in stages IA, IB, and IS is 20–30 Gy, delivered to
the infra diaphragmatic area including para-aortic and
iliac lymph nodes2. The patients involved in this study
were treated with 25 Gy in 16 daily fractions.
Previous investigations have shown that after the ra-
diotherapy patients show a wide variation of responses of
both tumor and normal tissues25. Our results also sus-
tain these reports. Although a significant portion of
inter-individual variations may be attributed to treat-
ment-related factors, such as dose distribution, dose in-
homogeneity and the patient size, an increased evidence
show that the major factors determining these differ-
ences are related to intrinsic biological factors and ge-
netic predisposition30,31.
The assessment of background DNA damage in pa-
tients involved in the present study also confirmed this
assumption. We found out that the pre-therapy levels of
DNA damage in peripheral blood leukocytes of cancer pa-
tients were substantially different. In some patients DNA
damage was comparable to background values recorded
in the age-matched healthy men, both from the control
group and from the healthy Croatian population studied
earlier32, while in others it was significantly increased.
Since the DNA damage detected by the alkaline comet
assay stands for a balance between the induction of le-
sions and their repair, a lower damage level in an individ-
ual may be the result of an actually lower number of le-
sions or of a high efficiency of repair33. One part of the
inter-individual variation is certainly related to age and
some life-style factors (especially smoking habits), as
well as their previous medical, i.e. diagnostic, exposu-
res34–38, while the other part is related to inherited bio-
logical factors. Other authors who applied the alkaline
comet assay in biomonitoring cancer patients reported
similar results and found that the presence of malignant
tumors itself caused significantly increased levels of DNA
damage as compared to the healthy population39–41.
We observed that prolonged exposure to ionizing radi-
ation during the radiotherapy cycle leads to possible
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adaptive response in peripheral blood leukocytes in the
majority of treated patients. Other authors also reported
the same phenomenon. Small acute single doses of ioniz-
ing radiation produce damages in a very short time.
Many of these are double-strand breaks of the DNA. Un-
der normal conditions cells have to cope with almost 106
damages due to reactive oxygen species produced by nor-
mal metabolic activity42,43. The DNA double strand bre-
aks induced by the acute, low radiation dose may be suffi-
cient to activate induced resistance, which may protect
cells even against damage due to metabolism. The adap-
tation induced by low doses of radiation is attributed to
the induction of a novel efficient chromosome break re-
pair mechanism which, if active at the time of challenge
with high doses, would lead to less residual damage44.
Previous investigations also indicate that the human
population exhibits heterogeneity in the adaptive re-
sponse to ionizing radiations that might be, at least in
part, genetically determined45. The results of our study
are also in agreement with these observations.
DNA double strand breaks induced by ionizing radia-
tion, if non- or misrepaired, lead to chromosomal aberra-
tions. From the results obtained here the existence of a
wide variability before treatment in the baseline fre-
quency of CA among cancer patients is evident. Our re-
sults provide evidence that local radiotherapy induced
significant levels of chromosome aberrations such as
dicentrics and acentric fragments in circulating blood
lymphocytes. The analysis of the CA frequency in blood
samples collected in the course of radiotherapy, and also
in the follow-up, indicates a wide variability. This result
is in agreement with previous reports38,46. These studies
also indicated that the short time interval between deliv-
eries of irradiation would result in complex time-depend-
ent patterns of DNA damage. The similar was noted in
our study as well. When individual values were compared
with their own control, no specific pattern was observed.
In some patients the rate of dicentrics declined with time
elapsing after exposure, while in others it was not ob-
served. Obviously, there are many factors which contrib-
uted to the non-uniform response to irradiation. Heavily
damaged cells which are more prone to death, disap-
peared and are replaced with new cells. Consequently,
the level of chromosome aberrations as recorded six
months and one year after the last treatment showed a
tendency to lower values. This decline in most subjects
reached the mean value similar to that observed in the
pre-treatment. The recovery of induced CA in lympho-
cytes of cancer patients after the cessation of radiother-
apy has also been observed in other studies38.
The results of the CBMN assay performed on the
same blood samples correlated well with the analysis of
structural chromosome aberrations. Radiation-induced
increase of micronuclei frequency was observed in cul-
tures of all the patients studied. The large variation in
micronuclei frequencies observed in the course of the
study may result from the selective elimination or mi-
totic arrest of cells with multiple chromosome aberra-
tions and subsequent replenishment with newly formed
cells without aberrations. In this study we observed a de-
cline of MN frequency during the follow-up period. In
some patients, however, MN levels were still slightly
higher than those observed before treatment. Frequen-
cies of persistent MN would depend on the balance be-
tween the amount of cytogenetic damage, cell killing and
related induction of proliferative responses in normal
cell precursors47. The decline to baseline may be the re-
sult of the repair of induced lesion, replacement of dam-
aged lymphocytes from a pool of imbalanced precursors
or a combination of these processes38.
All together the results of the present study demon-
strate how adjuvant therapeutic irradiation influenced
the biomarker levels. Therefore, we assume that the data
reported here might be potentially interesting to the
medical researchers working in the area of radiotherapy.
It is well-known that the results obtained in studies on
small populations are often complex to interpret, mainly
due to inter-individual variability. Although we also dis-
covered a certain degree of inter-individual variability in
the patient population, the results obtained for the refer-
ent group speak in favour of the fact that the biomarkers
were properly selected and confirm that they did not vary
with time.
As expected, the damage inflicted by radiotherapy in
seminoma patients was a reversible effect and regardless
of what assay is being used, it increased from baseline
and returned to baseline (or near baseline) after adju-
vant radiotherapy ended. Our results clearly show that
all biomarkers employed were able to sensitively respond
to different doses of radiation delivered throughout the
radiotherapy. With respect to their own specificity, the
comet assay and both cytogenetic assays confirmed sensi-
tive during the post-radiation and the follow-up period
too. We observed that even a long time after the thera-
peutic radiation ended all endpoints were able to de-
tected subtle differences between DNA/chromosome da-
mage in lymphocytes of the seminoma patients involved
in the study. These findings speak in favour of their use
for biomonitoring purposes in cancer patients after the
successful therapy.
Another interesting observation of this study is that
biomarkers in seminoma patients reach a peak at differ-
ent times since the start of radiotherapy. As capacities for
the repair of DNA lesions significantly differ among indi-
viduals, it is not surprising that cytogenetic biomarkers
reach a peak later than the comet assay. Different re-
sponses to irradiation might also be related to an adap-
tive protection that develops as a physiological stress re-
sponse relatively slowly, within a few hours after radia-
tion and may last from several weeks to months48. It is
also possible that seminoma patients who were exposed
daily to low doses of radiation had different efficiencies of
chromosome break repair mechanisms.
Our findings suggest that the responses to therapeu-
tic irradiation should be studied on individual basis. As
the outcome of the radiation exposure depend both on
the physical dose and the individual radiosensitivity, the
knowledge of individual radiation sensitivity is extre-
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mely important for the individualization of radiotherapy.
To be exact, it allows the therapist to apply either higher
tumor doses (and improve the local tumor control with-
out harming the normal tissue) or lower tumor doses
(and avoid severe side effects in the normal tissue) than
it is usually done49. In the present study we discovered
that the biomarkers employed had complementary val-
ues in the assessment of radiotherapy-induced primary
and residual DNA damage in patients with seminoma.
Taken together, these endpoints might be successfully
employed to a study of individual radiosensitivity.
Regardless of the benefits of radiotherapy, therapeu-
tic exposure to ionizing radiation may also lead to the in-
duction of secondary cancers in the treated area. The lev-
els of DNA damage, as recorded in lymphocytes, might
correlate with the levels of the damage produced by ther-
apy in other non-target cells or tissues. Although the ma-
jority of lesions induced by ionizing radiation are suc-
cessfully repaired in a relatively short time after expo-
sure13,50,51, a part of DNA damage still remains unre-
paired. It is assumed that radiation-induced reciprocal
translocations and dicentrics in lymphocytes are formed
in equal proportion. Cells that carry unstable aberra-
tions, such as dicentrics, disappear in the subsequent mi-
tosis, and dicentrics yields decrease rapidly after irradia-
tion. The lesions in DNA that are not repaired may result
in DNA mutations, RNA mutations leading to mutated
proteins and blocks to DNA replication, biological conse-
quences which may result in the onset of cancer29. In this
view, translocation frequency which is eliminated in the
decades after exposure presents an increased risk for de-
veloping secondary cancers.
The results of the present study point to the increases
in the frequency of genetic damage induced by radiother-
apy in the patients with seminoma of testes, indicating
an increased risk of secondary malignancies develop-
ment. Literature brings evidence of the persistent ge-
nome damage in somatic cells of patients with a long sur-
vival after the successful chemo/radiotherapy. The pres-
ence of a higher number of structural chromosomal aber-
rations in some cancer patients as detected during the
follow-up period points to chromosome instability. The
patients with an unstable genome, as seems to be the
case in the present study, are more susceptible to second-
ary cancers. Aberrations detected in these patients are
mostly balanced rearrangements, probably without grea-
ter functional importance. However, chromosome breaks
may occur at the loci of important genes which then re-
main modified in the target tissue. These sites are impor-
tant as potential sources of new neoplastic transfor-
mations52.
Early detection of repair-deficient patients may pro-
vide arguments for a stricter follow-up and prevention in
the management of many human cancers. As the major-
ity of patients with testicular cancer are 20–30 years of
age when the tumor is discovered, genetic changes in-
duced by therapy in their genome may not only cause
secondary cancers in cured patients, but perhaps also
transgenerational genetic diseases. Sensitive techniques,
as those employed in the present study, undoubtedly
might help in detection of genotoxic effects induced in
vivo by radiotherapy. As cytogenetic screening may de-
tect high-risk individuals, it might be useful in regular
medical monitoring of seminoma patients after the suc-
cessful therapy.
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CITOGENETI^KI NADZOR BOLESNIKA SA SEMINOMOM TESTISA LIJE^ENIH ADJUVANTNOM
RADIOTERAPIJOM
S A @ E T A K
Seminomi testisa su osjetljivi na terapiju zra~enjem. Incidenca ovog karcinoma zna~ajno se pove}ala tijekom po-
sljednjeg desetlje}a osobito u mla|oj populaciji. Iako je terapija seminoma testisa vrlo uspje{na, od velike je va`nosti
izu~iti o{te}enje genoma nastalo tijekom tereapije i prepoznati mogu}e zdravstvene rizike. Istra`ivanje je provedeno na
skupini od 10 bolesnika s dijagnosticiranim seminomom stadija I; pT1/2N0M0S0, koji su nakon operativnog zahvata
orhidektomije lije~eni adjuvantnom radioterapijom na podru~je paraaortalnih i istostranih ilija~nih limfnih ~vorova.
Bolesnici su primili ukupnu dozu zra~enja od 25 Gy podijeljenu u 16 dnevnih frakcija. Kako bismo utvrdili postoji li u
bolesnika pove}ana nestabilnost genoma prije radioterapije, usporedili smo ih s referentnom skupinom od 10 zdravih
mu{karaca odgovaraju}e dobi. Primjenom komet-testa u alkalnim uvjetima, analize kromosomskih aberacija i mikro-
nukleus testa u limfocitima periferne krvi istra`ene su razine primarnih o{te}enja DNA te o{te}enja kromosoma, kao i
dinamika njihova popravka. Svakom ispitaniku uzeta su ~etiri uzorka krvi za vrijeme terapije: prije i nakon {to su
primili prvu frakciju zra~enja, u sredini i nakon zavr{enog ciklusa zra~enja. Dva su uzorka krvi uzimana za vrijeme
post-terapijskog pra}enja bolesnika, {est mjeseci i godinu dana nakon zavr{ene radioterapije. Utvr|eno je da primjena
ve} prve frakcije zra~enja u gotovo svih bolesnika izaziva zna~ajan porast razine o{te}enja DNA u odnosu na pred-
-terapijske vrijednosti. U uzorcima krvi analiziranim u sredini ciklusa, te nakon primitka zadnje doze zra~enja uo~eni
su specifi~ni obrasci o{te}enja koji ukazuju i na mogu}i adaptivni odgovor u nekih bolesnika. Za vrijeme radioterapije
porasle su i razine strukturnih o{te}enja kromosoma i u~estalost mikronukleusa u limfocitima, a njihove se vrijednosti
uglavnom sni`avaju tijekom post-terapijskog razdoblja. Dobiveni rezultati potvr|uju postojanost post-radijacijskih o{te-
}enja u limfocitima (a mogu}e i u drugim ne-ciljnim stanicama) koja predstavljaju potencijalni rizik za pojavu sekun-
darnih karcinoma. Kako je ve}ina bolesnika u doba kad im se postavlja dijagnoza karcinoma testisa mla|e dobi, oni
predstavljaju osjetljivu populaciju koja zahtijeva posebnu pozornost. Budu}i da se citogeneti~kim metodama mogu ot-
kriti pojedinci pod povi{enim rizikom, ove metode mogu biti korisne u redovitom zdravstvenom nadzoru nad bole-
snicima sa seminomom testisa nakon provedene adjuvantne radioterapije.
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